The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. MRT5500 is being developed under a collaboration and license agreement between Sanofi Pasteur and Translate Bio. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 12, 2021

Biond Biologics announced today that it has entered into a potentially $1 billion global licensing agreement with Sanofi to take a joint stab at defeating advanced forms of cancer with a more comprehensive and expedited approach to immuno-oncology. . Keitma/Shutterstock. Co-Founder and Chief Executive Officer at Biond.

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

The Pharma Data

JUNE 26, 2021

We’ve all witnessed the promise of mRNA technology during this pandemic and are now looking to extend that promise to select annual vaccines ”, said Jean-François Toussaint, Global Head of Research and Development, Sanofi Pasteur. “ The trial follows successful preclinical research which demonstrated promising safety and immunogenicity.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Codon

FEBRUARY 13, 2024

Goodsell, RCSB Protein Data Bank and Scripps Research. 1 Yet even after more than two decades of research, media hype, and dozens of clinical trials and biotech start-ups that have come and gone, phage therapy has not scaled. Tom Ireland writes about the companies and technologies that are reimagining phage therapy.

Therapies 117

Therapies DNA Virus Clinical Trials 117

Drug Target Review

OCTOBER 10, 2024

What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? Furthermore, fostering cross-industry collaboration is essential.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

Codon

JULY 14, 2024

The creation of synthetic blood is one of the holy grails of biomedical research as it would alleviate such shortages and overcome current barriers to obtaining and storing blood products. Despite the high costs, researchers in Kyoto generated enough cultured platelets in 2022 to transfuse a 55-year-old woman for an initial human trial.

Production 133

Production Clinical Trials Trials Therapies 133

Codon

SEPTEMBER 29, 2024

The lab created a plan with eight research institutions across three continents. At best, the corporations with the best models released weak versions to the public under non-commercial licenses. Models of life became the dominant research paradigm in nearly every life-sciences field. However, no such dataset existed.

Engineering 132

Engineering Virus DNA Therapies 132

The Pharma Data

JANUARY 17, 2021

It was co-sponsored by Merck and Bayer, conducted with the scientific oversight of the Canadian VIGOUR Centre and the Duke Clinical Research Institute. By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses. Aurinia Pharmaceutical’s Voclosporin for Lupus Nephritis.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

JANUARY 31, 2021

Curing HIV remains the ultimate aspiration for Gilead’s HIV research and development efforts. Gritstone’s vaccine technology has the potential to educate the immune system to specifically recognize and destroy HIV-infected cells by leveraging SAM and adenoviral vectors. This press release features multimedia. About Gilead Sciences.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

JANUARY 17, 2021

Immuno-oncology is a leading research priority because it uses the body’s own immune system to effectively treat some types of cancer. Syngeneic tumor animal models play a critical role because they use standard inbred mice that have a competent immune system, which is required to evaluate immune-modulating therapies.

Immune Response 40

Immune Response Pharmacokinetics Engineering Licensing 40

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses.

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

DECEMBER 15, 2020

However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. The human monoclonal antibody targets specific immune plasma cells. New Immune System Cell.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

FEBRUARY 22, 2021

Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. vice president of immunology at Lilly.

Clinical Development 40

Clinical Development Small Molecule Clinical Trials Immune Response 40

The Pharma Data

MARCH 29, 2022

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein16 and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

SEPTEMBER 7, 2021

We are also participating in partnerships and research efforts to advance diagnostics and treatments for COVID-19 and supporting relief efforts across the globe. Contributions to Research, Life-Sciences Industry. Our Clinical Trials and Research.

Clinical Trials 52

Clinical Trials Vaccine Virus Trials 52

The Pharma Data

MARCH 25, 2022

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(10) and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

AUGUST 22, 2021

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales. About AstraZeneca.

Trials 52

Trials Vaccine Virus Pharmacokinetics 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., The EUA is temporary and does not take the place of a formal biologics license application (BLA) submission review and approval process and the use of the antibody cocktail remains investigational.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Department of Health and Human Services.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

SEPTEMBER 9, 2020

Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We producing CD8+ T cell responses, which is thought to promote an anti-viral effect. In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, Jansen, Ph.D.,

Vaccine 52

Vaccine RNA Clinical Trials Trials 52

Agency IQ

MARCH 7, 2024

explained JERRY WEIR, FDA’s director of the Division of Viral Products in the Office of Vaccines Research and Review in the Center for Biologics Evaluation and Research (CBER), at a VRBPAC meeting last year. Featuring previous research by Kari Oakes. service members and dependents.

Vaccine 40

Vaccine FDA Virus Licensing 40

The Pharma Data

DECEMBER 20, 2020

This oncolytic virus has induced long-lasting antitumor immune responses and abscopal effects in several tumor models, and its activity is further enhanced through combination with an anti-PD-1 antibody treatment. The Company’s validated, proprietary F.I.R.S.T

Virus 40

Virus Trials Clinical Trials Clinical Development 40

New Drug Approvals

DECEMBER 16, 2023

3 Additionally, iptacopan has the benefit of targeting factor B, which only affect the alternative complement pathway, leaving the classic and lectin pathway untouched for the body to still mount adequate immune responses against pathogens. of patients experienced a sustained hemoglobin improvement without transfusions respectively.

FDA 62

FDA Small Molecule FDA Approval Treatment 62

The Pharma Data

JANUARY 4, 2021

We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University. Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells. Barber is an associate professor of biology and director of the Office of Student Research.

Molecular Biology 40

Molecular Biology Therapies Immune Response Science 40

The Anticancer Fund

JUNE 23, 2023

Our intention is to help bring these findings to the attention of the broader cancer research community. All articles need to be critically assessed and viewed in their broader research context. Please get in touch if you’re interested in discussing research based on the findings presented below ( info@anticancerfund.org ).

Drugs 52

Drugs Trials Clinical Trials Treatment 52

The Pharma Data

DECEMBER 20, 2020

efficacy, according to the state-run Gamaleya research center and the Russian Direct Investment Fund (RDIF). The data demonstrated the vaccine elicited a combined adaptive humoral and cellular immune response and also provided insights into the composite nature of BNT162b2-induced T-cell immunity.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

JUNE 18, 2021

Senior Vice President and Head of Vaccine Research & Development, Pfizer. With a single injection, PREVNAR 20 provides adults with strong and meaningful protection against serotypes responsible for the majority of circulating pneumococcal disease around the world.”. Jansen, Ph.D., IMPORTANT SAFETY INFORMATION.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

AUGUST 20, 2020

T cell immune responses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron. Regeneron has shared these results with the U.S.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

SEPTEMBER 15, 2020

I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. THERAPEUTIC AREAS OF FOCUS.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 9, 2020

During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

Codon

JULY 27, 2023

I could write an entire article in response, but if you want to go deeper into this subject, I suggest you read it in full. For a recent study, researchers edited 21 different genes in poplar trees, a species commonly used to make paper. The researchers studied trees with 70,000 different gene-editing combinations, just 0.5%

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

I could write an entire article in response, but if you want to go deeper into this subject, I suggest you read it in full. For a recent study, researchers edited 21 different genes in poplar trees, a species commonly used to make paper. The researchers studied trees with 70,000 different gene-editing combinations, just 0.5%

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Department of Health and Human Services.

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

DECEMBER 17, 2020

Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. “The investigational cocktail is now available to indicated high-risk U.S. patients under an Emergency Use Authorization, and we also continue a robust clinical development program.”

Hospitals 52

Hospitals Production Clinical Trials Therapies 52